Clinical trials for Endocrinology/Metabolism specialty

  • Status: Not currently enrolling


    The oral sugar test (OST) has been developed as a new test for diagnosing the glucose and insulin problems involved in the development of laminitis (founder) in horses.  This new test is easily performed and provides more information than just a single blood sample.  However, we do not know enough about the consistency of results, so this study is being conducted to compare results of two tests performed 7 to 14 days apart.

    The OST involves fasting your horse and then collecting 3 blood samples (20 mL each) from the jugular vein using a needle before and 60 and 90 minutes after giving corn syrup (0.15 ml/kg) by mouth.  Our fasting procedure is as follows:

    •         For an OST beginning between 8:00 and 10:00 AM, we ask you to bring your horse into a dirt paddock or stall and leave only one flake of hay at 10 PM the night before.
    •         For an OST beginning between 4:00 and 6:00 PM, we ask you to bring your horse into a dirt paddock or stall and leave only one flake of hay at 6:00 AM the same morning.

    Inclusion Criteria:

    Horses with suspected or confirmed glucose and insulin problems associated with equine metabolic syndrome (EMS) or Cushing’s disease (also called pituitary pars intermedia dysfunction).

    Horse owners must allow their horse to be tested twice 7-14 days apart.

    Exclusion Criteria:

    Horses that are currently suffering from other diseases.  For example, any medical problem causing fever.

    Blood samples must be collected without causing significant stress, so horses with a fear of needles are excluded.

    Client Benefits:

    This study covers the cost of measuring glucose and insulin in the blood samples collected, but horse owners are financially responsible for costs associated with two veterinarian visits to farm and professional time for performing the tests.

    Contact Information:

    Diane Welsh, Clinical Trial Technician   clinicaltrials@tufts.edu                                                               '




  • Status:  Currently enrolling


    The goal of this study is to assess the presence and degree of vascular abnormalities which are thought to exist within the eyes of diabetic canines. Diabetes is one of the most common endocrinopathies affecting dogs. In humans, diabetes results in microangiopathies (diabetic iridopathy and retinopathy) which are significant vision threatening sequelae. While noted to occur in diabetic canines, little published information exists regarding its degree and/or severity. This study will perform a diagnostic work up, including a 24 hour blood glucose curve, in addition to, ocular angiography using both sodium fluorescein and indocyanine green, in a total of 8 diabetic canines. Our goal is to document and characterize vasculature changes (vascular leakage, delayed perfusion) which are thought to occur in diabetic dogs and correlate them to disease status and/or duration. Data generated herein, will provide the necessary information for conducting longitudinal studies, correlating the prevalence and severity of these vascular abnormalities to the duration of disease and regulation status. Knowledge regarding the prevalence and severity of these vascular abnormalities could translate into better preventative medicine and/or improved patient outcomes following surgery (i.e. cataract surgery) in our canine patients.

    Inclusion Criteria

    1. New or previously diagnosed canines with diabetes mellitus. A diagnosis of diabetes mellitus is based on a history of polyuria, polydipsia, polyphagia, blood glucose above 250mg/dl, and glucosuria.

    Exclusion Criteria

    1. Diabetic canines exhibiting any signs/symptoms suggestive of concurrent systemic disease(s) will not be considered.  Excluding conditions include diseases that cause insulin resistance such as hyperadrenocorticism and/or those which may be associated with vascular abnormalities (i.e.renal failure, neoplasia, and heart failure)
    • Dogs receiving corticosteroids within the previous 30 days will be excluded.

     Client benefits

    The study will cover the following costs associated with participation in this study: the cost of a complete blood count, serum biochemistry profile, urinalysis and culture. Additionally, costs of conducting a 24 hours blood glucose curve (including hospitalization charges) and a fructosamine level will be covered. For angiographic purposes, canines will be sedated the following day and receive intravenous administration of two commonly employed angiographic dyes. The study will cover the costs associated with conducting ocular angiography.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

  • Status:  Currently enrolling


    We hypothesize that the orally administered drug, bexagliflozin, will improve glycemic control in poorly regulated diabetic cats. The primary objective of this study is to determine if mean blood sugar and fructosamine concentrations decrease by ≥10% with administration of bexagliflozin over a two week period. The secondary objective is to determine if bexagliflozin is well tolerated by poorly regulated diabetic cats.

    Inclusion Criteria:

    Cats with unregulated diabetes mellitus based on history of persistent hyperglycemia(>250 mg/dl) and appropriate clinical signs, including polyuria, polydipsia and weight loss

    Exclusion Criteria:

    Cats with documented azotemia, elevated bilirubin, ALT >2.5x the upper limit of normal, diabetic ketoacidosis, urinary tract infection, use of corticosteroids within the past 8 weeks, heart disease requiring medication and uncontrolled hyperthyroidism based on preliminary laboratory testing

    Client benefits:

    The study will cover the costs of blood work and urine tests required for the study, blood pressure measurement, day boarding as well as the cost of the medication.  We will be teaching you how to monitor your cat's blood glucose levels at home with a hand held glucometer that will be loaned from our hospital for the duration of the study.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu